Quantcast
Home > Quotes > MGTA

Magenta Therapeutics, Inc. Common Stock (MGTA) Quote & Summary Data

MGTA 
$7.49
*  
0.43
5.43%
Get MGTA Alerts
*Delayed - data as of Dec. 13, 2018  -  Find a broker to begin trading MGTA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    MGTA Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 8.43 / $ 7.25
Share Volume
144,313
50 Day Avg. Daily Volume
63,571
Previous Close
$ 7.92
52 Week High / Low
$ 16.33 / $ 6.10
Market Cap
248,305,027
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
144,313
50 Day Avg. Daily Volume:
63,571

Trading Range

The current last sale of $7.49 is 22.79% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 8.43 $ 16.33
 Low: $ 7.25 $ 6.10

Company Description (as filed with the SEC)

For more than 50 years, doctors and patients have had difficult conversations about bone marrow transplant: the procedure can save patients' lives and cure them of disease, but the risk of toxicity and even mortality is often a significant deterrent. At Magenta, we believe we can refocus that conversation on the cure and enable many more patients with devastating diseases such as severe autoimmune diseases, including multiple sclerosis; blood cancers, including leukemia; and genetic diseases such as sickle cell disease to benefit from advances in transplant medicine. We are a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients. Transplant is a well-established and often curative medical procedure, and emerging data on stem cell gene therapy, which is bone marrow transplant using gene-modified stem cells, suggest the potential for meaningful benefit with this newer form of transplant.  ... More ...  


Risk Grade

Where does MGTA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 7.92
Open Date:
Dec. 13, 2018
Close Price:
$ 7.49
Close Date:
Dec. 13, 2018

Consensus Recommendation

Analyst Info